eli-002 7p
·Code: ELI-002 7P
eli-002 7p: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Elicio Therapeutics, Inc. (ELTX) | Phase 1/Phase 2 |
Clinical Trials (1)
Expanded Access Protocol for ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC)
Frequently asked questions
Who is developing eli-002 7p?
eli-002 7p is being developed by Elicio Therapeutics, Inc..
How many clinical trials involve eli-002 7p?
BioSniper tracks 1 clinical trial involving eli-002 7p.
Get deeper analysis on eli-002 7p
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis